A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
Improving HIV Treatment in Children and Adolescents ... which is the most common cancer in people living with ... Common HIV Treatments May Aid Alzheimer's Disease Patients Apr. 16, 2024 ...
Bedford Today on MSN6d
New HIV cases hit record high in BedfordUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
The U.S. Centers for Disease Control and Prevention (CDC) and the President's Emergency Plan for AIDS Relief (PEPFAR), have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback